SILARUS THERAPEUTICS
Silarus Therapeutics is developing therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders. Erythroferrone is a recently-discovered hormone that regulates the iron supply for red blood cell production. Iron deficiency, also known as anemia, is a condition in which blood does not contain the normal amount of red blood cells or lacks the proper amount of hemoglobin. This, in turn, lowers the amount of oxygen-rich blood in circulation, causing shortness of breath, dizziness or headaches.
SILARUS THERAPEUTICS
Industry:
Health Care Medical Therapeutics
Founded:
2014-01-01
Address:
La Jolla, California, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
10 M USD
Similar Organizations
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Current Employees Featured
Sanford Madigan Chief Business Officer @ Silarus Therapeutics
Chief Business Officer
Tighe Reardon Chief Financial Officer @ Silarus Therapeutics
Chief Financial Officer
Tomas Ganz Scientific & Co-Founder @ Silarus Therapeutics
Scientific & Co-Founder
Jay Lichter President & Chief Executive Officer @ Silarus Therapeutics
President & Chief Executive Officer
Elizabeta Nemeth Scientific & Co-Founder @ Silarus Therapeutics
Scientific & Co-Founder
Founder
Investors List
GlaxoSmithKline
GlaxoSmithKline investment in Series A - Silarus Therapeutics
Avalon Ventures
Avalon Ventures investment in Series A - Silarus Therapeutics
More informations about "Silarus Therapeutics"
Silarus Therapeutics Company Profile 2024: Valuation, …
Silarus Therapeutics General Information Description. Developer of therapeutic treatment designed to treat iron deficiency and iron overload disorders. The company's therapeutic treatment targets Erythroferrone which is a recently …See details»
Silarus Therapeutics - Funding, Financials, Valuation & Investors
Silarus Therapeutics is funded by 2 investors. GlaxoSmithKline and Avalon Ventures are the most recent investors. Silarus Therapeutics has a post-money valuation in the range of $10M to …See details»
Silarus Therapeutics is developing erythroferrone-targeting ...
Silarus Therapeutics will receive up to $10 million in Series A financing and R&D support from Avalon Ventures and GSK. Silarus Therapeutics was founded based on intellectual property …See details»
Silarus Therapeutics - Tech Company Profile - Gaebler.com …
Silarus Therapeutics is developing therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders. Erythroferrone is a recently-discovered hormone that …See details»
Silarus Therapeutics | UCLA TDG
Silarus Therapeutics is developing therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders.See details»
Silarus Therapeutics - VentureRadar
Silarus Therapeutics is developing therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders. Erythroferrone is a recently-discovered hormone that …See details»
Silarus Therapeutics - Products, Competitors, Financials, …
Silarus Therapeutics is developing therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders. Erythroferrone is a recently-discovered hormone that …See details»
Silarus Therapeutics - Contacts, Employees, Board Members
Organization. Silarus Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. About. …See details»
Silarus Therapeutics Inc. - BioCentury Company Profiles - BCIQ
Silarus Therapeutics Inc. - BioCentury Company Profiles for the biopharma industrySee details»
Erythroferrone Undergoing Commercial Development
Silarus Therapeutics is developing erythroferrone-targeting treatments for iron deficiency, ... Silarus was founded based on intellectual property in-licensed from investigators Tomas Ganz, M.D., Ph.D., Professor of Medicine, Department of …See details»
Research programme: erythroferrone modulators - Silarus …
Silarus Therapeutics is developing erythroferrone modulators for the treatment of iron deficiency anaemia and iron overload. Erythroferrone is a hormone that Research programme: …See details»
GlaxoSmithKline, Avalon launch a pair of new build-to-buy biotechs
Sep 22, 2014 GlaxoSmithKline and San Diego-based Avalon Ventures have crafted two new biotechs which will explore the therapeutic potential of a pair of new drugs. These companies, …See details»
Silarus Therapeutics Inc - Company Profile and News
Company profile page for Silarus Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
What You Need to Know About Silarus Therapeutics - BioSpace
Dec 17, 2015 Silarus Therapeutics is developing therapeutics that target erythroferrone for the treatment of iron deficiency and iron overload disorders. A recently-discovered hormone, …See details»
Avalon Ventures and COI Pharmaceuticals Announce First …
May 20, 2016 “We have quickly achieved our first milestones at Sitari Pharmaceutical and Silarus Therapeutics because of the dedication of our team at COI Pharmaceuticals and the …See details»
Silarus Therapeutics is Developing Erythroferrone-Targeting ...
Silarus Therapeutics will receive up to $10 million in Series A financing and R&D support from Avalon Ventures and GSK. Silarus Therapeutics was founded based on intellectual property …See details»
Silarus Therapeutics Inc. | Insights
Jun 15, 2015 Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Avalon-GSK Collaboration Generates Two More Startups in San …
Sep 22, 2014 GlaxoSmithKline and Avalon Ventures have generated two additional start-ups as part of their 2013 collaboration, Xconomy reported Monday. The first start-up, Silarus …See details»
Drugging erythroferrone to treat anemias | Blood - American …
Feb 20, 2020 Conflict-of-interest disclosure: T.G. is a scientific founder and shareholder of Silarus Therapeutics and Intrinsic LifeSciences and serves as a consultant to Global Blood …See details»